Given the heterogeneity of CLL cytoskeletal features, patient‐tailored therapeutic approaches are crucial and it might be useful to take into account the nature of BCR subsets and autonomous signaling, together with the CD49d status. This evidence concerns the gene ITGA4 and B-cell chronic lymphocytic leukemia.